SCHEMBL7128643

SCHEMBL7128643

Cc1[nH]c(C=O)c(C)c1CN1CCN(C2CC2)CC1

nearest known ligand 0.35

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TRPV6 Q9H1D0 6/20 0.35
ALDH1A1 P00352 5/20 0.35
RGS12 O14924 1/20 0.35
RECQL P46063 1/20 0.33
SMN1; SMN2 Q16637 1/20 0.33
KDM4E B2RXH2 3/20 0.31
MEN1 O00255 2/20 0.31
KMT2A Q03164 2/20 0.31
MAPT P10636 1/20 0.31
HTT P42858 1/20 0.31
HPGD P15428 1/20 0.31
HSD17B10 Q99714 1/20 0.31
CCR5 P51681 1/20 0.31
MAPK1 P28482 1/20 0.30
PDGFRB P09619 1/20 0.30
FGFR1 P11362 1/20 0.30
KDR P35968 1/20 0.30
CHRM2 P08172 1/20 0.30
CHRM4 P08173 1/20 0.30
CHRM5 P08912 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7244667 0.83 BAZ2A (0.33) ALDH1A1KDM4EMEN1KMT2AMAPT
SCHEMBL5401530 0.83 MCL1 (0.40) ALDH1A1KDM4EMEN1KMT2AMAPT
SCHEMBL7117376 0.83 ALDH1A1 (0.34) ALDH1A1KDM4EMEN1KMT2AMAPT
SCHEMBL6092642 0.82 ALOX15 (0.42) ALDH1A1KDM4EMEN1KMT2AMAPT
SCHEMBL7125283 0.81 PDGFRB (0.34) ALDH1A1KDM4EMEN1KMT2AMAPT
SCHEMBL7593513 0.80 LMNA (0.36) ALDH1A1MEN1KMT2AHSD17B10CHRM2
SCHEMBL6089632 0.78 HSD17B10 (0.44) ALDH1A1SMN1; SMN2KDM4EMEN1KMT2A
SCHEMBL7118384 0.78 PDE5A (0.37) ALDH1A1SMN1; SMN2KDM4EMEN1KMT2A
SCHEMBL260659 0.77
SCHEMBL7125898 0.76 ALDH1A1 (0.43) ALDH1A1SMN1; SMN2KDM4EHTTHPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6599902-B2 For treating or preventing a protein kinase related disorder SUGEN, INC. 2003-07-29 US disclosed
US-20030125370-A1 5-ARALKYSUFONYL-3-(PYRROL-2-YLMETHYLIDENE)-2-INDOLINONE DERIVATIVES AS KINASE INHIBITORS SUGEN, INC. 2003-07-03 US disclosed
WO-2002096361-A2 5-ARALKYLSULFONYL-3- (PYRROL-2-YLMETHYLIDENE)-2-INDOLINONE DERIVATIVES AS KINASE INHIBITORS SUGEN, INC. (US) 2002-12-05 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030125370-A1 5-ARALKYSUFONYL-3-(PYRROL-2-YLMETHYLIDENE)-2-INDOLINONE DERIVATIVES AS KINASE INHIBITORS DMPK, ADK, MAP3K20 TRPV6 3522/4885ALDH1A1 2773/4885RGS12 2070/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.